Human epidermal growth factor receptor 2 (HER2)–positive (HER2+) breast cancers make up  15% to 20% of all breast tumors. In ...

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...

ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early ...

A retrospective study sought to confirm real-world outcomes of patients with HER2+ breast cancer treated with trastuzumab deruxtecan.

Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact.

Resistant cells demonstrated global decreases in DNA accessibility with localized opening at resistance-driving loci, ...

What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...

"Therapy for small, node-negative, HER2-positive breast cancer can be challenging due to the risk of overtreatment. Our study can help assess outcomes of patients according to specific tumor sizes and ...

At the San Antonio Breast Cancer Symposium (SABCS), a large retrospective analysis of U.S. electronic health records compared outcomes for patients with HER2-positive metastatic breast cancer who ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer. Antibody-drug conjugates, or ADCs, have had a tremendous impact on the ...